Similar safety profiles on OX40 monotherapy have been observed in other recent clinical trials studying ICAGN01949 (fully humanised agonistic OX40 IgG1 mAb), GSK3174998 (fully humanised agonistic IgG1 mAb), or ivuxolimab (alias: PF-04518600; fully humanised agonistic IgG2 mAb) in advanced solid tumours and ivuxolimab in AML, respectively (132–135). Here, TNFRSF4 is linked to acute myeloid leukemia.